石四药集团(02005)：氨吡啶已获国家药监局批准登记成为在上市制剂使用的原料药

Core Viewpoint - The company Shijiazhuang Fourth Pharmaceutical Group has received approval from the National Medical Products Administration of China for its active pharmaceutical ingredient, Amaprine, marking it as the first in the country to be approved for use in marketed formulations [1] Group 1 - Amaprine is a potassium channel blocker primarily used to improve walking speed in adults with certain types of multiple sclerosis [1]